Our mission is to transform the landscape of cancer treatment by delivering effective and life-extending therapies to patients facing the most challenging diagnoses.
This innovative method, though technically and conceptually distinct, proved to be a crucial advancement. While early cell proliferation assays faced significant challenges, including theoretical and practical hurdles that led to disappointing clinical trial results and a well-publicized setback in the New England Journal of Medicine, Dr. Weisenthal remained committed to his vision.
For the next 30 years, Dr. Weisenthal dedicated his career to refining and advancing the cell death assay. He collaborated closely with Dr. Grace and other forward-thinking physicians and researchers, sharing his knowledge and discoveries through publications, symposia, and personal communications.
This unwavering commitment laid the groundwork for the groundbreaking work now being conducted by Cytometric Therapeutics, Inc. (CTI). The lessons learned from the past, coupled with our innovative triple-drug combination, are driving our mission to develop products to revolutionize end-stage cancer treatment.
The pioneering spirit of Dr. Weisenthal, and the collaborative work with Dr. Grace, forms the very foundation of CTI. We are building upon this legacy to provide hopeby developing effective therapies to patients who have exhausted all other options.
This foundation of cell death assays, and the long term collaboration between Dr. Weisenthal and Dr. Grace, has led to the development of the CTI triple drug combination, which are currently undergoing clinical trials.